Valuation: BIONOMICSSADR

Market Cap 23.03M 16.03M 14.28M 13.06M 11.9M 22.42M 1.51B 157M 62.75M 802M 60.15M 58.86M 2.53B P/E 2027 *
-1.23x
P/E 2028 * -1.21x
Enterprise Value 23.03M 16.03M 14.28M 13.06M 11.9M 22.42M 1.51B 157M 62.75M 802M 60.15M 58.86M 2.53B EV / Sales 2027 *
-
EV / Sales 2028 * -
Free-Float
94.98%
Yield 2027 *
-
Yield 2028 * -
3 years 0.18
Extreme 0.176999
4.73
5 years 0.18
Extreme 0.176999
22
10 years 0.18
Extreme 0.176999
22
Change 5-day change 1-year change 3-year change Capi.($)
+4.20%-.--% - - 16.13M
+3.80%+8.47%+64.65%+77.70% 66.87B
+1.63%+6.76%+24.52%+104.31% 56.55B
+0.07%+2.39%+11.12%+75.17% 57.2B
+0.41%-3.70%+26.06%+33.51% 43.47B
-11.04%-6.63%+199.38%+724.74% 42.8B
+2.51%+4.22%+20.49%+97.44% 42.95B
+1.59%-6.02%+92.48%+79.95% 32.11B
+7.50%+13.28%+28.05%+64.46% 34.01B
-1.13%-2.54%-41.80%+356.21% 24.13B
Average +0.97%+3.98%+47.22%+179.28% 44.45B
Weighted average by Cap. +0.72%+3.91%+49.51%+163.49%

Financials

2027 *2028 *
Net sales - -
Net income -24.59M -17.12M -15.25M -13.95M -12.7M -23.95M -1.62B -168M -67.02M -857M -64.24M -62.86M -2.7B -29.17M -20.3M -18.09M -16.55M -15.07M -28.4M -1.92B -199M -79.48M -1.02B -76.19M -74.56M -3.21B
Net Debt - -
Logo BIONOMICSSADR
Neuphoria Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. Its lead drug candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, as-needed treatment of social anxiety disorder and for the chronic treatment of post-traumatic stress disorder. BNC210 is a well-tolerated, broad-spectrum antianxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. In addition, the Company has two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.
Employees
1